(Q46520823)

22 December 2017

title

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial (English)

1 reference

22 December 2017

0 references

1 reference

2

Hans-Peter Hartung

1 reference

22 December 2017

9

Ludwig Kappos

1 reference

22 December 2017

6

Giancarlo Comi

1 reference

22 December 2017

4

Massimo Filippi

1 reference

22 December 2017

Douglas S Goodin

1

Douglas S Goodin

1 reference

22 December 2017

Rupert Sandbrink

12

Rupert Sandbrink

1 reference

22 December 2017

Christoph Pohling

16

Christoph Pohl

1 reference

22 December 2017

Barry G W Arnason

5

Barry Arnason

1 reference

22 December 2017

Volker Knappertz

11

Volker Knappertz

1 reference

22 December 2017

Timon Bogumil

10

Timon Bogumil

1 reference

22 December 2017

Karola Beckmann

13

Karola Beckmann

1 reference

22 December 2017

BEYOND Study Group

17

BEYOND Study Group

1 reference

22 December 2017

author name string

Paul O'Connor

3

1 reference

22 December 2017

Stuart Cook

7

1 reference

22 December 2017

Douglas Jeffery

8

1 reference

22 December 2017

Rick White

14

1 reference

22 December 2017

John Petkau

15

1 reference

22 December 2017

publication date

27 September 2011

1 reference

22 December 2017

Multiple Sclerosis Journal

published in

1 reference

22 December 2017

volume

18

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

181-195

1 reference

22 December 2017

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

A novel sensitive and selective bioassay for human type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

An overview of methods for the analysis of longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

The clinico-radiological paradox in multiple sclerosis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511418629

21 January 2018

Identifiers

DOI

10.1177/1352458511418629

1 reference

22 December 2017

PubMed ID

21952094

1 reference

22 December 2017